凯投宏观: US-Iran talks stall, market optimism may soon fade
Svmuu reported that Jonas Galtman, an analyst at Capital Economics, said that if the US-Iran stalemate continues and the Strait of Hormuz remains largely closed, market optimism that the Iran war is about to be resolved could soon begin to fade. The analyst said: "Negotiations to end the US-Iran war and reopen the Strait of Hormuz appear to have stalled again, prompting global financial markets to adopt a cautious stance once again at the start of the new week. Time is not on the side of the optimists: every passing day exacerbates disruptions to energy markets, causing greater downstream damage to global economies." (Jin Shi)
Source:Odaily · Source Link
Disclaimer: This content reflects only the author’s personal views and does not constitute any investment or financial advice. If you discover any content that violates regulations,Click to Report
24H Trending
-
1
Billionaire investor Chase Coleman’s Tiger Global fund disclosed in its latest 13F filing that its top five growth stocks are all focused on AI infrastructure, including TSMC, NVIDIA, Amazon, Meta, and Google.
-
2
Liquidity Crunch in Cryptocurrency Mining: Causes and Analysis of the Current Situation in 2026
-
3
Analysis of CRYSTAL’s Value and Investment Potential: An Examination of Multiple Projects and Risk Assessment
-
4
Will the BEAM token go to zero? Could it rise to $1,000? An in-depth analysis of the Beam network and its market prospects
-
5
The analysis points out that Iran’s overlapping centers of power complicate efforts to end the war with the United States, and that the Revolutionary Guards possess significant operational autonomy.
-
6
Israeli West Bank Settler Tells BBC Attacks on Palestinians Are Justified as Revenge, Equating One Jewish Life to "10 Million" Palestinians
-
7
ETH2X-FLI-P: An Analysis of the 2x Leveraged Ethereum Index Token on Polygon
-
8
What Is CVP? An In-Depth Analysis of the PowerPool Ecosystem and the Investment Value of Its Token, CVP
-
9
Analysis: The State Street Healthcare ETF (XLV) has an expense ratio of 0.08% and a diversified portfolio, while the Invesco Biotechnology ETF (PBE) has an expense ratio of 0.58% and focuses on small-cap stocks; PBE is up 10.2% year-to-date, outperforming XLV.
-
10
Coldcard Wallet Incident Bitcoin: Estimated Losses Rise to $70 Million
Markets Today
Recommended Reading







